Clinical advancement of hypercoagulability in patients with ovarian cancer

冯征; 温灏; 吴小华

doi:10.3969/j.issn.1007-3969.2015.03.012

您当前的位置：

首页 >

文章列表页 >

Clinical advancement of hypercoagulability in patients with ovarian cancer

更新时间：2025-12-31

- Clinical advancement of hypercoagulability in patients with ovarian cancer
- China Oncology Vol. 25, Issue 3, Pages: 231-234(2015)
- 作者机构：
  
  复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.03.012
  CLC：
- Published Online：18 May 2015，
  
  Published：18 May 2015
- 稿件说明：
移动端阅览
冯征,温灏,吴小华. 卵巢癌患者血液高凝状态临床研究进展[J]. 中国癌症杂志, 2015, 25(3): 231-234.

冯征, 温灏, 吴小华. Clinical advancement of hypercoagulability in patients with ovarian cancer[J]. China Oncology, 2015, 25(3): 231-234.
冯征,温灏,吴小华. 卵巢癌患者血液高凝状态临床研究进展[J]. 中国癌症杂志, 2015, 25(3): 231-234. DOI： 10.3969/j.issn.1007-3969.2015.03.012.

冯征, 温灏, 吴小华. Clinical advancement of hypercoagulability in patients with ovarian cancer[J]. China Oncology, 2015, 25(3): 231-234. DOI： 10.3969/j.issn.1007-3969.2015.03.012.

摘要

卵巢癌患者的静脉血栓发生率远高于其他妇科肿瘤，约20%以上的卵巢癌患者存在高凝状态。肿瘤可导致血液高凝状态，而凝血功能的过度激活也极大地促进肿瘤的进展，是影响患者预后的重要因素。近年来，高凝状态逐渐成为卵巢癌研究领域的新热点，本文将对卵巢癌患者高凝状态的形成机制、临床意义及相关治疗进展进行综述。

Abstract

The incidence of venous thromboembolism in patients with ovarian cancer is much higher than other gynecologic cancers. Approximate 20% of ovarian cancer patients have hypercoagulable status during different phases of their disease. Ovarian cancer itself can induce hypercoagulability

but meanwhile the over activated coagulation system may promote disease progression. Coagulation system disorder is one of the most important prognostic factors in ovarian cancer. Recently

hypercoagulability becomes a hot spot in the ovarian cancer research field. This article reviews the mechanism of hypercoagulability

its clinical implication and correlated treatment in ovarian cancer patients.

关键词

Keywords

references

Views

3488

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer

Progress in treatment of gynecological cancer in 2023

Progress in diagnosis and treatment of mucinous ovarian cancer

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Progress in diagnosis and treatment of gynecological tumors in 2022

Related Author

Yanan TIAN

Hui ZHENG

Tianqing YAN

Heng ZHANG

Renquan LU

Lin GUO

Zheng FENG

Qinhao GUO

Related Institution

Department of Clinical Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, State Key Laboratory of Genetic Engineering, Fudan University, Institute of Thoracic Oncology, Fudan University, Department of Oncology, Shanghai Medical College, Fudan University

Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University

AI问答

⁰